Holen Sie sich die Stockscreener-App
11.13
3.15%
0.34
Vorhandelsmarkt:
11.10
-0.03
-0.27%
Schlusskurs vom Vortag:
$10.79
Offen:
$10.79
24-Stunden-Volumen:
220.85K
Relative Volume:
0.67
Marktkapitalisierung:
$623.47M
Einnahmen:
$2.22M
Nettoeinkommen (Verlust:
$-40.51M
KGV:
-8.6635
EPS:
-1.2847
Netto-Cashflow:
$-46.53M
1W Leistung:
+2.20%
1M Leistung:
+4.41%
6M Leistung:
-31.72%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.60
$11.32
1-Wochen-Bereich:
$10.60
$11.58
52-Wochen-Spanne:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Vergleichen Sie UPB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
11.13 | 623.47M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Deutsche Bank AG Invests $244,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
An Extremely Profitable Business Plans to Go Public. What Investors Need to Know. - The Globe and Mail
Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio names new chief technology officer By Investing.com - Investing.com South Africa
Upstream Bio names new chief technology officer - Investing.com Australia
Upstream Bio Appoints Stacy Price as Chief Technology Officer - GlobeNewswire
Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations - Nasdaq
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Tower Research Capital LLC TRC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Is Upstream Bio Inc (NASDAQ: UPB) A Good Investment Now? - Stocksregister
Wells Fargo & Company MN Invests $149,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
27,017 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by Barclays PLC - Defense World
MetLife Investment Management LLC Invests $181,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Brokers Offer Predictions for Upstream Bio Q2 Earnings - Defense World
Metric Analysis: Upstream Bio Inc (UPB)’s Key Ratios in the Limelight - DWinneX
Upstream Bio Advances Verekitug in Clinical Trials - TipRanks
Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position - TipRanks
Upstream Bio reports Q1 revenue $566k, consensus $326.25k - TipRanks
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewswire
Transpire Bio Announces R&D and Manufacturing Expansion - The Manila Times
Upstream Bio Fast-Tracks Clinical Trials: Key Data Coming Earlier for Revolutionary Respiratory Drug - Stock Titan
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,734 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Legal & General Group Plc - Defense World
Gold Price and Miners Look Less Shiny as Global Trade Tensions Begin to Ease - The Globe and Mail
JPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
LPL Financial LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF (NYSEARCA:PDN) - Defense World
Geode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Inc’s Banking’s 100-Day Moving Average at 11.87: Will the Stock Break Through? - investchronicle.com
Medical Properties Trust Inc (MPW) Stock: Navigating a Year of Volatility - investchronicle.com
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
Philip Morris International Inc (PM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):